Employees: 1001-5000
Investors 1
| Date | Name | Website |
| - | Saratoga I... | saratogain... |
Mentions in press and media 14
| Date | Title | Description |
| 21.03.2017 | Angiotech Pharmaceuticals Closes Financing Round of Undisclosed Amount | Angiotech Pharmaceuticals, a Vancouver, Canada-based medical device company focused on high value medical consumables in the wound closure and ophthalmology sectors, closed a financing round of undisclosed amount. The terms of the transacti... |
| 26.03.2013 | Angiotech hands $363M in interventional assets back to Argon Medical | Angiotech Pharmaceuticals plans to retire all of its outstanding debt obligations with part of the $362.5 million it stands to gain through the sale of its interventional products business back to Argon Medical Devices. Through the deal Arg... |
| 27.01.2011 | Rex Medical kills Angiotech deal, alleging breach of contract | Angiotech Pharmaceuticals Inc. (OTC:ANPI) received a termination notice for the licensing agreement it has with Rex Medical LP for its Option retrievable vena cava filter. Conshohocken, Pa.-based Rex Medical alleges that Angiotech "mat... |
| 14.01.2011 | Angiotech delisted from NASDAQ | Angiotech Pharmaceuticals Inc.’s (OTC:ANPI) shares are no longer traded on NASDAQ as of today. The Vancouver-based company failed to regain compliance with the stock exchange’s listing rules within a 180-day period that ended Jan. 3. NASDAQ... |
| 13.01.2011 | Stent drug maker Angiotech delisted from NASDAQ | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 04.10.2010 | Angiotech’s struggles continue as it defers $10 million debt payment | Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) deferred $9.7 million in interest payments on debt that were due Oct. 1, looking to "effectuate a transaction that would materially reduce the company’s existing debt levels," the company... |
| 24.09.2010 | Athersys touts positive results for stem cell treatment for heart attack patients | Athersys Inc. (NSDQ:ATHX) reported more positive results from an ongoing Phase 1 clinical trial of its adult stem cell therapy for the treatment of heart-attack patients. The new data show that Athersys’ MultiStem treatment was well-tolerat... |
| 30.07.2010 | Plunging Taxus sales continue to put the hurt on Angiotech | Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) is once again feeling the effects of sluggish sales of Boston Scientific Corp,’s (NYSE:BSX) Taxus coronary stent systems. The Vancouver-based company makes paclitaxel, the drug used in the stent’s ... |
| 16.02.2010 | Athersys finishes enrolling heart attack patients for stem cell therapy study | Athersys plans to use catheters to deliver its MultiStem therapy to the damaged regions of patients’ hearts during its studies at several U.S. cardiovascular treatment centers, including the Cleveland Clinic, Columbia University Medical C... |
| 09.01.2010 | Abbott’s Xience V stent wins Japanese clearance | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
Show more